These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 38725780)

  • 1. Expert Opinions on the Management of Hemophilia A in India: The Role of Emicizumab.
    Gupta N; Dutta A; Ahmed B; Ross CR; S C; Dolan G; John MJ; Radhakrishnan N; Aggarwal S; Seth T; Kaul V; Shah V
    Cureus; 2024 Apr; 16(4):e58941. PubMed ID: 38725780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.
    Olasupo OO; Noronha N; Lowe MS; Ansel D; Bhatt M; Matino D
    Cochrane Database Syst Rev; 2024 Feb; 2(2):CD014544. PubMed ID: 38411279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A.
    Zhou ZY; Raimundo K; Patel AM; Han S; Ji Y; Fang H; Zhong J; Betts KA; Mahajerin A
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1109-1120. PubMed ID: 32452276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
    Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
    Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imlifidase, a new option to optimize the management of patients with hemophilia A on emicizumab.
    Bou-Jaoudeh M; Mimoun A; Delignat S; Peyron I; Capdevila L; Daventure V; Deligne C; Dimitrov JD; Christophe OD; Denis CV; Lenting PJ; Proulle V; Lacroix-Desmazes S
    J Thromb Haemost; 2023 Oct; 21(10):2776-2783. PubMed ID: 37473843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Emicizumab: a paradigm shift in hemophilia treatment].
    Nogami K
    Rinsho Ketsueki; 2020; 61(5):536-541. PubMed ID: 32507821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emicizumab for hemophilia A without inhibitors.
    Cafuir L; Kruse-Jarres R; Mancuso ME; Kempton CL
    Expert Rev Hematol; 2019 Jul; 12(7):515-524. PubMed ID: 31130012
    [No Abstract]   [Full Text] [Related]  

  • 8. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial.
    Pipe SW; Collins P; Dhalluin C; Kenet G; Schmitt C; Buri M; Jiménez-Yuste V; Peyvandi F; Young G; Oldenburg J; Mancuso ME; Kavakli K; Kiialainen A; Deb S; Niggli M; Chang T; Lehle M; Fijnvandraat K
    Blood; 2024 Apr; 143(14):1355-1364. PubMed ID: 38127586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors.
    Carcao M; Mancuso ME; Young G; Jiménez-Yuste V
    Expert Rev Hematol; 2021 Feb; 14(2):143-148. PubMed ID: 33499681
    [No Abstract]   [Full Text] [Related]  

  • 10. A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab.
    Batt K; Schultz BG; Caicedo J; Hollenbeak CS; Agrawal N; Chatterjee S; Bullano M
    Curr Med Res Opin; 2022 Oct; 38(10):1685-1693. PubMed ID: 35880468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemophilia A: Emicizumab monitoring and impact on coagulation testing.
    Nardi MA
    Adv Clin Chem; 2023; 113():273-315. PubMed ID: 36858648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute treatment of intracranial hemorrhage complicated by hemophilia a and emicizumab therapy.
    Clark K; Patrick BM; Torian SC
    Am J Emerg Med; 2024 Feb; 76():272.e1-272.e2. PubMed ID: 38123423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in Hemophilia A Management.
    Cho S; Perry AM; Cheng AM; Wang C; Rico JF
    Adv Pediatr; 2022 Aug; 69(1):133-147. PubMed ID: 35985706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors.
    Ebbert PT; Xavier F; Seaman CD; Ragni MV
    Haemophilia; 2020 Jan; 26(1):41-46. PubMed ID: 31746522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.
    Mahlangu JN
    BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
    Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
    J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
    [No Abstract]   [Full Text] [Related]  

  • 17. Breakthrough bleeding episodes in pediatric severe hemophilia a patients with and without inhibitors receiving emicizumab prophylaxis: a single-center retrospective review.
    Hassan E; Motwani J
    Pediatr Hematol Oncol; 2022 Aug; 39(5):418-426. PubMed ID: 35170384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China.
    Liu G; Huang K; Li G; Zhen Y; Li Z; Chen Z; Wu R
    Front Pediatr; 2022; 10():992267. PubMed ID: 36340724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A.
    Müller J; Pekrul I; Pötzsch B; Berning B; Oldenburg J; Spannagl M
    Thromb Haemost; 2019 Sep; 119(9):1384-1393. PubMed ID: 31203578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, safety and cost of emicizumab prophylaxis in haemophilia A patients with inhibitors: A nationwide observational study in Taiwan.
    Shen MC; Chou SC; Chiou SS; Lin PC; Chen YC; Lin HY; Lee YC; Huang CE; Weng TF; Huang TH; Chung CY; Chen JS; Chen SH; Cheng SN; Hsiao CC; Huang YM; Chen SH; Yu YB; Lin SC; Lin CY; Peng CT; Wang JD;
    Haemophilia; 2023 Nov; 29(6):1499-1508. PubMed ID: 37819166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.